Please assess the completion status of the following clinical trial:

Trial Title: PK/PD of Vitamin D3 in Adults With CF

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For CF, diagnosis of CF based on positive sweat chloride or known CF mutation~* For CF, Patients with pancreatic insufficiency~* Age ≥ 18 years~* Serum 25(OH)D concentrations below 30 ng/mL (75 nmol/L)~Exclusion Criteria:~* Pregnancy~* History of lung transplant,~* Severe anemia (hemoglobin concentration \< 7 g/dL),~* Liver disease (AST/ALT \> 3x ULN), kidney disease (GFR ≤ 40 mL/min), or granulomatous conditions~* Patients taking steroids, cholesterol-lowering drug (cholestyramine), weight-loss drugs (orlistat) , statins, anti-tuberculosis drugs (rifampin and isoniazid), phenobarbital, phenytoin, carbamazepine, immunosuppressants (cyclosporine, tacrolimus)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adults with Cystic Fibrosis (Type: EXPERIMENTAL): CF adults with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
- Non-CF Controls with Low vitamin D (Type: EXPERIMENTAL): Non-CF controls with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)

Based on this trial design, predict the completion outcome and termination type (if applicable).